Intertek opens one of Europe's largest GMP pharmaceutical stability storage facilities

19 May 15

Intertek the leading quality solutions provider to industries worldwide today opened a new 8000 ft² 190000 litre pharmaceutical stability storage facility in Royston UK in response to increased client demand and enabling the company to broaden the range of solutions it can offer to the global pharmaceutical industry.

Based in Cambridge the heartland of the UK's pharma and biotech industry the new pharmaceutical stability storage facility is part of a wider investment programme in Intertek's global pharmaceutical capabilities. It also complements Intertek's existing product development services for pharmaceuticals consumer healthcare biologics medical devices and nutraceuticals both in Melbourn and globally. This new facility will enable clients globally to establish recommended and bespoke storage conditions with a state-of-the-art environmental monitoring system.

With the opening of this new Good Manufacturing Practice (GMP)-compliant facility Intertek as a leading provider of analytical and formulation support for the pharmaceutical biotechnology and drug delivery industries has increased its stability storage capacity significantly enabling the growing demands for bespoke storage conditions risk management / contingency storage programs and 'storage-only' projects to be met.

Mark Hammond Laboratory Director shared "This new facility integrated with our scientists' experience and knowledge of pharmaceutical testing will bring a range of storage solutions with options for client bespoke conditions and risk management storage to meet the increased demands from our global clients."

Chetan Parmar Senior Vice President of Intertek Life Sciences said "With over 20 years of experience in the design and management of pharmaceutical stability studies Intertek's new facility will benefit our clients through a truly flexible stability outsourcing partnership."

Harriet Fear CEO of One Nucleus an international membership organisation for life science and healthcare companies based in Cambridge said: "Research and development lie at the heart of the pharmaceutical industry which invests more than any other industrial sector in the UK with up to approximately £11.5 million spent every day. It is great to see that Intertek is supporting global clients in their research and development by investing in this impressive stability storage facility in the heart of Europe's largest life science and healthcare cluster."

Intertek UK & Eire Chief Executive Rob van Dorp said "Intertek has over 20 years of experience in analytical testing and formulation for the inhaled products behind treatments for Asthma Cystic Fibrosis Diabetes and Chronic Obstructive Pulmonary disease and has built a reputation for providing outstanding and responsive customer service for challenging pharmaceutical developments programs. The team are therefore well placed to expand the range of solutions they can provide for clients who are developing ever more complex products."

GMP stability testing forms a key part of Intertek's pharmaceutical development services. Intertek's global International Conference on Harmonisation (ICH) stability storage and testing locations also include Manchester (UK) Whitehouse (New Jersey USA) and Melbourne (Australia). Intertek has a 20 year heritage providing cGMP contract analytical bioanalytical stability and formulation support as well as regulatory affairs services.

Notes to editors

Intertek is a leading quality solutions provider to industries worldwide. From auditing and inspection to testing training advisory quality assurance and certification Intertek adds value for its customers by helping improve the quality and safety of their products assets and processes. With a network of more than 1000 laboratories and offices and over 38000 people in more than 100 countries Intertek supports companies' success in the global marketplace by helping customers to meet end users' expectations for safety sustainability performance integrity and desirability in virtually any market worldwide.

Visit www.intertek.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150519005103/en/

Business Wire
http://www.businesswire.com/

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.